

## Genmab

Price DKK850.00

The CASTOR study is positive... A first step towards large market expansion!

Fair Value DKK1300 vs. DKK1170 (+53%)

BUY-Top Picks

Bloomberg	GEN DC
Reuters	GEN.CO
12-month High / Low (DKK)	954.0 / 514.0
Market Cap (DKKm)	50,726
Ev (BG Estimates) (DKKm)	47,346
Avg. 6m daily volume (000)	413.3
3y EPS CAGR	-12.3%

	1 M	3 M	6 M	31/12/15
Absolute perf.	0.8%	-8.0%	41.3%	-7.4%
Healthcare	-2.7%	-13.6%	-6.4%	-12.8%
DJ Stoxx 600	0.9%	-8.9%	-0.7%	-7.9%

YEnd Dec. (DKKm)	2015	2016e	2017e	2018e
Sales	1,133	866.7	906.4	1,306
% change		-23.5%	4.6%	44.1%
EBITDA	554	50.1	2.7	351
EBIT	730.4	50.1	2.7	351.2
% change		-93.1%	-94.5%	NM
Net income	587.3	85.1	42.7	396.2
% change		-85.5%	-49.8%	NM

	2015	2016e	2017e	2018e
Operating margin	64.5	5.8	0.3	26.9
Net margin	67.4	9.8	4.7	30.3
ROE	21.9	2.4	1.2	9.9
ROCE	-15,400	44.2	11.1	69.2
Gearing	-100.2	-94.6	-89.4	-85.8

(DKK)	2015	2016e	2017e	2018e
EPS	9.71	1.41	0.71	6.55
% change		-85.5%	-49.8%	NM
P/E	87.5x	NS	NS	NS
FCF yield (%)	0.4%	0.0%	0.1%	NM
Dividends (DKK)	0.00	0.00	0.00	0.00
Div yield (%)	NM	NM	NM	NM
EV/Sales	41.7x	54.6x	52.4x	36.2x
EV/EBITDA	85.2x	944.1x	17279.3x	134.7x
EV/EBIT	64.7x	944.1x	17279.3x	134.7x

Genmab has announced that its Phase III trial evaluating daratumumab in combination with bortezomib and dexamethasone (namely CASTOR) was stopped early for benefit, and met its primary endpoint of improving progression free survival (PFS) vs bortezomib/dexamethasone. This is of course very positive as 1) JNJ (which retains dara's rights) should be able to obtain a first label expansion from the FDA to second-line patients with such data, 2) we are not ruling out increased off-label use of daratumumab in combo with a proteasome inhibitor, whether bortezomib or carfilzomib, in coming months. The next step would be the publication of top-line results for another Phase III study (POLLUX), which this time is evaluating "dara" in combination with lenalidomide and dexamethasone. And once again, we are quite confident in its outcome... BUY reiterated with a FV of DKK1,300 vs DKK1,170.

## ANALYSIS

- Genmab has announced that the Phase III evaluating daratumumab (anti-CD38) in combination with bortezomib and dexamethasone (CASTOR) met its primary endpoint of improving progression free survival (PFS) in a pre-planned interim analysis ( $p \leq 0.0001$ ). We have no details regarding the extent of this enhancement, but we note that an IDMC (Independent Data Monitoring Committee) recommended to stop the trial early due to benefit... So we would not be surprised to see a hazard ratio or HR ranging from 0.5 to 0.7, as seen with BMS's nivolumab in some solid tumors (irrespective of the PD-L1 status), or even Amgen's carfilzomib in multiple myeloma.

Fig. 1: Data from drugs for which the trial was stopped early

Drug	Indication	Setting	Median PFS
Nivolumab	1L BRAF Melanoma	Monotherapy vs dacarbazine	5.1 vs 2.2 months (HR: 0.43)
Nivolumab	2L NSCLC	Monotherapy vs docetaxel	3.5 vs 2.8 months (HR: 0.62)
Nivolumab	2L Advanced RCC	Monotherapy vs everolimus	4.6 vs 4.4 months (HR: 0.88)
Carfilzomib	2/3L Myeloma	Combo with len/dex vs len/dex	26.3 vs 17.6 mpnths (HR: 0.69)
Carfilzomib	2/3L Myeloma	Combo with dex vs bort/dex	18.7 vs 9.4 months (HR: 0.53)

Source : Companies Data; Bryan Garnier &amp; Co. ests.

- Obviously, this is very positive news as 1/ with such data, JNJ (which retains dara's WW rights) should then be able to get a first label expansion from the FDA to second-line patients (whereas the previous label was "limited" to double-refractory ones as a single-agent); 2/ we think approval could be obtained by the end of this year, assuming a priority review by the FDA in the next three months; 3/ we are not ruling out increased off-label use of daratumumab in combo with a proteasome inhibitor, whether bortezomib or carfilzomib, in coming months.... and notably following the presentation of detailed results (perhaps at the ESMO conference?). As a consequence, FY2016 sales guidance of USD250-300m now looks even more conservative to us...
- The next step would be the publication of top-line results for another Phase III study (POLLUX), which this time is evaluating "dara" in combination with lenalidomide and dexamethasone. And here again, we are confident in its outcome given that 1/ this anti-CD38 has so far generated best-in-class data in heavily pre-treated patients either as a single-agent (See Fig. 2), or as part of a combination regimen (and remarkably with immunomodulatory agents like lenalidomide – given the strong(er) synergies between these two approaches); 2/ even BMS's elotuzumab (an anti-CS1), which we consider a much less potent therapeutic option, has yielded positive Phase III results in a similar setting (see Fig. 3).
- We think this data could be the most important from a market penetration point of view... especially if it were to show a stronger improvement in PFS and OS compared to Amgen's carfilzomib in a similar setting, along with a more satisfying safety profile (and we think they could do, given what we saw in the GEN503 study – see our latest report [here](#) for more details). As such, we are sticking to our peak sales of EUR5.5bn for dara in multiple myeloma... at least for the moment.




**Fig. 2: Single-agent therapies in R/R multiple myeloma**

Drugs	Settings	Responses
Carfilzomib	R/R patients (median of 5 prior lines)	ORR: 23.7%, CR: 0.4%, VGPR: 5.0%, PR: 18.3%
Carfilzomib	R/R patients (median of 5 prior lines)	ORR: 19.1%
Daratumumab	Double refractory (median of 5 prior lines)	ORR: 29.2%, CR: 3%, VGPR: 9%, PR: 17%
Daratumumab	R/R patients (median of 4 prior lines)	ORR: 35%, CR: 10%, VGPR: 5%, PR: 20%
SAR650984	R/R patients (median of 5 prior lines)	ORR: 33%, CR: 11%, PR: 22%
MOR202	R/R patients (median of 4 prior lines)	ORR: 33% (PR and VGPR) with dexamethasone
Pomalidomide	R/R patients (median of 5 prior lines)	ORR: 18%, CR: 2%, PR: 16%
Elotuzumab	R/R patients (median of 5 prior lines)	ORR: 0%, SD: 26.5%

Source : Companies Data; Bryan Garnier & Co. ests.

**Fig. 3: BMS' elotuzumab in combination with lenalidomide/dexamethasone (ELOQUENT-2)**



Source : BMS

**VALUATION**

- We have raised our FV from DKK1,170 to DKK1,300 after having 1/ slightly increased our probability of success (70% vs 60%) for daratumumab as a second-line treatment for patients with multiple myeloma, and 2/ decreased our WACC for this very same setting (9.0% vs 10.0% previously). **BUY recommendation reiterated.**
- Importantly, our FV could be further increased by +DKK50-100 should POLLUX be positive.

**NEXT CATALYSTS**

- **Q2 2016:** European approval of daratumumab as a monotherapy for the treatment of double-refractory or heavily pre-treated patients (who have received at least three prior lines of therapy) with multiple myeloma.
- **H1 2016:** Top-line results from the POLLUX study (Phase III evaluating daratumumab in combination with lenalidomide and dexamethasone in with myeloma who received more than one therapy).
- **H2 2016:** Read-across for ofatumumab (an anti-CD20) from the likely approval of Roche's ocrelizumab (another anti-CD20) in multiple sclerosis (and notably in RRMS).

[Click here to download](#)



**Analyst :**  
 Mickael Chane Du  
 33(0) 1 70 36 57 45  
 mchanedu@bryangarnier.com

**Sector Team :**  
 Eric Le Berrigaud  
 Hugo Solvet

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

## Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

## Distribution of stock ratings

BUY ratings 64%

NEUTRAL ratings 28.7%

SELL ratings 7.4%

# Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

<b>London</b>	<b>Paris</b>	<b>New York</b>	<b>Geneva</b>	<b>New Delhi</b>
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062
Financial Conduct Authority	the Autorité de Contrôle prudentiel et de		FINMA	
(FCA)	resolution (ACPR)			

#### **Important information**

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..